Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
12.82
-1.34 (-9.46%)
At close: Apr 10, 2025, 4:00 PM
12.80
-0.02 (-0.17%)
After-hours: Apr 10, 2025, 8:00 PM EDT
Teva Pharmaceutical Revenue
In the year 2024, Teva Pharmaceutical had annual revenue of $16.54B with 4.40% growth. Teva Pharmaceutical had revenue of $4.23B in the quarter ending December 31, 2024, a decrease of -5.12%.
Revenue (ttm)
$16.54B
Revenue Growth
+4.40%
P/S Ratio
0.88
Revenue / Employee
$449,199
Employees
36,830
Market Cap
14.69B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TEVA News
- 1 day ago - Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha
- 3 days ago - Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention - GlobeNewsWire
- 10 days ago - New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable - GlobeNewsWire
- 14 days ago - Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 - GlobeNewsWire
- 14 days ago - Teva Releases Q1 2025 Aide Memoire - GlobeNewsWire
- 27 days ago - Drugmakers agree to participate in second round of price negotiations - Reuters
- 4 weeks ago - Teva Pharmaceutical Industries Limited (TEVA) Leerink's 2025 Global Healthcare Conference (Transcript) - Seeking Alpha
- 4 weeks ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript) - Seeking Alpha